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In a letter to the editor Dr. Hottenrott provides valuable
comments [1] on our survey describing international pre-
operative rectal cancer management [2]. In our opinion,
three key messages are derived from our survey: First, most
surgeons agree to neoadjuvant treatment when there is an
increased risk of ﬁnding histologically positive circumfer-
ential margins. In addition, we found more than 40 other
indications for neoadjuvant treatment (see our Table 4).
This emphasizes the need for an international agreement,
as different indications for neoadjuvant treatment will
select noncomparable groups of patients in outcome
studies.
Second, we have shown (see our Table 6) that multi-
disciplinary team (MDT) meetings signiﬁcantly inﬂuence
several important decisions in preoperative rectal cancer
management. Interestingly, centers with regular MDT have
a higher rate of using magnetic resonance imaging (MRI)
(Odds Ratio [OR] = 3.62) and consider a threatened cir-
cumferential resection margin (CRM) as indication for
neoadjuvant treatment (OR = 5.67). We believe that MDT
improves preoperative management of rectal cancer by
increasing adherence to national guidelines. Similar dis-
cussions in international rectal cancer societies are needed
aiming towards an international consensus statement.
Finally, our survey revealed sparse use (35% of all
cases) of MRI. The goal for the radiologic examination in
rectal cancer is to explore the tumor’s relation to nearby
anatomical structures. This evaluation will conclude with
TNM staging, important for chemoradiotheraphy, surgical
treatment, and prognosis. Magnetic resonance imaging has
a central role in this evaluation and should be the ﬁrst
choice radiologic modality [3]. Not only is MRI crucial in
detection of TNM stage but also plays a central role in
determination of the tumor’s distance to the mesorectal
fascia and the CRM. Magnetic resonance imaging has
moderate sensitivity on T1 and T2 tumors, and should be
supplemented with rectal ultrasound.
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18F-ﬂuorodeoxyglucose positron emission
tomography (PET) was used by 55% in selected cases and
by 1% in all cases. In our opinion PET has no central role
in primary management of rectal cancer [4]; however, we
believe PET will gain increased importance in management
of rectal cancer in the future.
Biologically targeted agents for adjuvant and neoadju-
vant treatment are promising treatment options; however,
patient selection and prediction of treatment effects remain
problematic [5].
The wide variations in practice for preoperative man-
agement of rectal cancer should alert national and inter-
national rectal cancer experts as well as health care
administrators. This will inﬂuence health care costs, side
effects, quality of life, local recurrence, and cancer-speciﬁc
survival.
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